We disagree with Laffon and Marthan that the prognostic value of baseline metabolic tumour volume (MTV) depends on the outlining method. One of our study aims was to compare the accuracy of various segmentation methods in predicting survival [1] . We found in our cohort of 147 consecutive patients with diffuse large B cell lymphoma (DLBCL) treated at a single institution that all methods (SUV ≥2.5, SUV ≥41% of SUVmax and SUV ≥mean liver uptake) predicted progression-free and overall survival with similar accuracy. Instead, it was the optimal cut-off values for predicting survival that were dependent on the method, which is an important distinction.
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This indicates that baseline MTV is a robust predictor of outcomes in DLBCL, but as stated in the discussion in our paper and reiterated by Laffon and Marthan, standardization of the methodology used to measure MTV is required. We believe that a collaborative effort is needed to validate measurement of tumour burden in international patient datasets, in a manner previously adopted for the standardization of methods for response assessment in lymphoma, using the Deauville criteria [2] [3] [4] . In agreement with Laffon and Marthan, we consider that standardization of the methodology should include the method used to segment the tumour volume and the PET acquisition protocol [5] , including uptake time and reconstruction methods.
Regarding statistical analyses, none of the comparative combinations described by Laffon and Marthan revealed a normal distribution, so we remain convinced that a nonparametric approach was more appropriate. In addition, the aim was to describe quantitative differences between the MTV methods rather than to explore the relationships between them. With our study it would not have been possible to explore in detail how agreement varies with MTV value, but the large percentage variances calculated by Laffon and Marthan are based on median values, while the larger individual discrepancies contributing to the high upper limits of agreement in Figs. 1 and 3a of our study [1] appear well above the median (indicating a lower relative difference for those measurements). While we agree that the discrimination revealed by the ROC curves is fair but not strong, the survival analysis revealed highly significant differences between the high-risk and low-risk groups according to MTV for the cut-off values found for all methods.
We thank Laffon and Marthan for concluding that our work addressed an important issue. We stand by the findings, while acknowledging the limitations discussed, that in our dataset the 2.5 method was the easiest to use and gave the best interobserver agreement, using two different softwares, although all methods were prognostic. The cut-off value of 400 ml using the SUV ≥2.5 method is in line with the cut-off values reported by an independent group using SUV ≥2.5 in different populations of patients with DLBCL [6, 7] . It is a given that there will be more uncertainty about how MTV affects prognosis in patients with data points that lie close to the 400-ml cut-off value. This applies to any measurement that lies close to a binary threshold, and refinement with larger datasets would reduce the degree of uncertainty.
Nonetheless measurement of disease burden remains an important parameter for study [8] and will no doubt become integrated into preclinical risk assessment of patients in the not too distant future.
